These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34952937)

  • 1. Mechanisms and modulation of sepsis-induced immune dysfunction in children.
    Mithal LB; Arshad M; Swigart LR; Khanolkar A; Ahmed A; Coates BM
    Pediatr Res; 2022 Jan; 91(2):447-453. PubMed ID: 34952937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocortisone treatment is associated with a longer duration of MODS in pediatric patients with severe sepsis and immunoparalysis.
    Bline KE; Moore-Clingenpeel M; Hensley J; Steele L; Greathouse K; Anglim L; Hanson-Huber L; Nateri J; Muszynski JA; Ramilo O; Hall MW
    Crit Care; 2020 Sep; 24(1):545. PubMed ID: 32887651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and Personalized Intervention for Infection and Sepsis.
    Beckmann N; Salyer CE; Crisologo PA; Nomellini V; Caldwell CC
    Surg Infect (Larchmt); 2020 Nov; 21(9):732-744. PubMed ID: 32240042
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new normal: immunomodulatory agents against sepsis immune suppression.
    Hutchins NA; Unsinger J; Hotchkiss RS; Ayala A
    Trends Mol Med; 2014 Apr; 20(4):224-33. PubMed ID: 24485901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options.
    Hamers L; Kox M; Pickkers P
    Minerva Anestesiol; 2015 Apr; 81(4):426-39. PubMed ID: 24878876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation during sepsis in organ transplanted children.
    Angele MK; Loehe F; Faist E
    Minerva Pediatr; 2005 Oct; 57(5):259-68. PubMed ID: 16205609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New frontiers in precision medicine for sepsis-induced immunoparalysis.
    Bruse N; Leijte GP; Pickkers P; Kox M
    Expert Rev Clin Immunol; 2019 Mar; 15(3):251-263. PubMed ID: 30572728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring immunomodulation in patients with sepsis.
    Kyriazopoulou E; Giamarellos-Bourboulis EJ
    Expert Rev Mol Diagn; 2021 Jan; 21(1):17-29. PubMed ID: 33183116
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.
    Wynn JL; Neu J; Moldawer LL; Levy O
    J Perinatol; 2009 Feb; 29(2):79-88. PubMed ID: 18769381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis.
    Muszynski JA; Nofziger R; Moore-Clingenpeel M; Greathouse K; Anglim L; Steele L; Hensley J; Hanson-Huber L; Nateri J; Ramilo O; Hall MW
    Am J Respir Crit Care Med; 2018 Aug; 198(3):361-369. PubMed ID: 29470918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision Immunotherapy for Sepsis.
    Peters van Ton AM; Kox M; Abdo WF; Pickkers P
    Front Immunol; 2018; 9():1926. PubMed ID: 30233566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed.
    Kumar V; Sharma A
    J Chemother; 2008 Dec; 20(6):672-83. PubMed ID: 19129063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Design of Nested Adaptive Clinical Trials of Multiple Organ Dysfunction Syndrome Children in a Single Study.
    VanBuren JM; Hall M; Zuppa AF; Mourani PM; Carcillo J; Dean JM; Watt K; Holubkov R
    Pediatr Crit Care Med; 2023 Dec; 24(12):e635-e646. PubMed ID: 37498156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory therapy for sepsis: an update.
    Christaki E; Anyfanti P; Opal SM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1013-33. PubMed ID: 22029521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards personalized medicine: a scoping review of immunotherapy in sepsis.
    Slim MA; van Mourik N; Bakkerus L; Fuller K; Acharya L; Giannidis T; Dionne JC; Oczkowski SJW; Netea MG; Pickkers P; Giamarellos-Bourboulis EJ; Müller MCA; van der Poll T; Wiersinga WJ; ; Vlaar APJ; van Vught LA
    Crit Care; 2024 May; 28(1):183. PubMed ID: 38807151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.
    Joshi I; Carney WP; Rock EP
    Front Immunol; 2023; 14():1130214. PubMed ID: 36825018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of HIV infection on the host response to bacterial sepsis.
    Huson MA; Grobusch MP; van der Poll T
    Lancet Infect Dis; 2015 Jan; 15(1):95-108. PubMed ID: 25459220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.